A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors
The purpose of the study is to evaluate the safety/tolerability, pharmacokinetics, and preliminary efficacy of GFH018 in combination with Toripalimab in patients with advanced solid tumors.
Advanced Solid Tumor
DRUG: GFH018|DRUG: Toripalimab
Phase Ibï¼šIncidence of dose-limiting toxicity (DLT) events, 28 days|Phase II: ORR (Objective Response Rate), approximately 6 months after first dose
The purpose of the study is to evaluate the safety/tolerability, pharmacokinetics, and preliminary efficacy of GFH018 in combination with Toripalimab in patients with advanced solid tumors.